HLH as an additional warning sign of inborn errors of immunity beyond familial-HLH in children: a systematic review.

familial hemophagocytic lymphohistiocytosis hemophagocytic lymphohistiocytosis hemophagocytic syndrome immune deficiency inborn errors of immunity macrophage activation syndrome

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2024
Historique:
received: 25 08 2023
accepted: 29 01 2024
medline: 28 2 2024
pubmed: 28 2 2024
entrez: 28 2 2024
Statut: epublish

Résumé

Hemophagocytic Lymphohistiocytosis (HLH) is a rare and life-threatening condition characterized by a severe impairment of the immune homeostasis. While Familial-HLH (FHL) is a known cause, the involvement of other Inborn Errors of Immunity (IEI) in pediatric-HLH remains understudied. This systematic review aimed to assess the clinical features, triggers, laboratory data, treatment, and outcomes of pediatric HLH patients with IEI other than FHL (IEInotFHL), emphasizing the importance of accurate identification and management. A systematic search for studies meeting inclusion criteria was conducted in PubMed, EMBASE, MEDLINE, and Cochrane Central. Quality assessment was performed through JBI criteria. A comprehensive search yielded 108 records meeting inclusion criteria, involving 178 patients. We identified 46 different IEI according to IUIS 2022 Classification. Combined immunodeficiencies, immune dysregulation disorders, and phagocyte defects were the IEI most frequently associated with HLH. In 75% of cases, HLH preceded the IEI diagnosis, often with an unrecognized history of severe infections. Triggers reflected the specific infection susceptibilities within IEI groups. Liver and central nervous system involvement were less common than in FHL cases. Treatment approaches and outcomes varied, with limited long-term follow-up data, limiting the assessment of therapeutic efficacy across IEI groups. A comprehensive evaluation encompassing immunological, infectious, and genetic aspects is essential in pediatric-HLH. Relying solely on FHL or EBV susceptibility disorders tests is insufficient, as diverse other IEI can contribute to HLH. Early recognition of HLH as a potential warning sign can guide timely diagnostic investigations and facilitate tailored therapeutic interventions for improved outcomes. https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=371425, PROSPERO, CRD42022371425.

Sections du résumé

Background UNASSIGNED
Hemophagocytic Lymphohistiocytosis (HLH) is a rare and life-threatening condition characterized by a severe impairment of the immune homeostasis. While Familial-HLH (FHL) is a known cause, the involvement of other Inborn Errors of Immunity (IEI) in pediatric-HLH remains understudied.
Objective UNASSIGNED
This systematic review aimed to assess the clinical features, triggers, laboratory data, treatment, and outcomes of pediatric HLH patients with IEI other than FHL (IEInotFHL), emphasizing the importance of accurate identification and management.
Methods UNASSIGNED
A systematic search for studies meeting inclusion criteria was conducted in PubMed, EMBASE, MEDLINE, and Cochrane Central. Quality assessment was performed through JBI criteria.
Results UNASSIGNED
A comprehensive search yielded 108 records meeting inclusion criteria, involving 178 patients. We identified 46 different IEI according to IUIS 2022 Classification. Combined immunodeficiencies, immune dysregulation disorders, and phagocyte defects were the IEI most frequently associated with HLH. In 75% of cases, HLH preceded the IEI diagnosis, often with an unrecognized history of severe infections. Triggers reflected the specific infection susceptibilities within IEI groups. Liver and central nervous system involvement were less common than in FHL cases. Treatment approaches and outcomes varied, with limited long-term follow-up data, limiting the assessment of therapeutic efficacy across IEI groups.
Conclusion UNASSIGNED
A comprehensive evaluation encompassing immunological, infectious, and genetic aspects is essential in pediatric-HLH. Relying solely on FHL or EBV susceptibility disorders tests is insufficient, as diverse other IEI can contribute to HLH. Early recognition of HLH as a potential warning sign can guide timely diagnostic investigations and facilitate tailored therapeutic interventions for improved outcomes.
Systematic review registration UNASSIGNED
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=371425, PROSPERO, CRD42022371425.

Identifiants

pubmed: 38415256
doi: 10.3389/fimmu.2024.1282804
pmc: PMC10896843
doi:

Types de publication

Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1282804

Informations de copyright

Copyright © 2024 Ricci, Sarli, Lodi, Canessa, Lippi, Dini, Ferrari, Pisano, Sieni, Indolfi, Resti and Azzari.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Silvia Ricci (S)

Department of Health Sciences, University of Florence, Florence, Italy.
Immunology Division, Section of Pediatrics, Meyer Childrens Hospital IRCCS, Florence, Italy.

Walter Maria Sarli (WM)

Department of Health Sciences, University of Florence, Florence, Italy.
Immunology Division, Section of Pediatrics, Meyer Childrens Hospital IRCCS, Florence, Italy.

Lorenzo Lodi (L)

Department of Health Sciences, University of Florence, Florence, Italy.
Immunology Division, Section of Pediatrics, Meyer Childrens Hospital IRCCS, Florence, Italy.

Clementina Canessa (C)

Immunology Division, Section of Pediatrics, Meyer Childrens Hospital IRCCS, Florence, Italy.

Francesca Lippi (F)

Immunology Division, Section of Pediatrics, Meyer Childrens Hospital IRCCS, Florence, Italy.

Donata Dini (D)

Department of Pediatrics, Meyer Childrens Hospital IRCCS, Florence, Italy.

Marta Ferrari (M)

Department of Pediatrics, Meyer Childrens Hospital IRCCS, Florence, Italy.

Laura Pisano (L)

Department of Pediatrics, Meyer Childrens Hospital IRCCS, Florence, Italy.

Elena Sieni (E)

Pediatric Hematology-Oncology Department, Meyer Childrens Hospital IRCCS, Florence, Italy.

Giuseppe Indolfi (G)

Department of Pediatrics, Meyer Childrens Hospital IRCCS, Florence, Italy.
Department Neurofarba, University of Florence, Florence, Italy.

Massimo Resti (M)

Department of Pediatrics, Meyer Childrens Hospital IRCCS, Florence, Italy.

Chiara Azzari (C)

Department of Health Sciences, University of Florence, Florence, Italy.
Immunology Division, Section of Pediatrics, Meyer Childrens Hospital IRCCS, Florence, Italy.

Classifications MeSH